Lansoprazol Abz (Lansoprazole)

Lansoprazole acts as an acid‑reduction therapy and is indicated for several gastrointestinal disorders.

• Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining higher gastric pH, improving symptom control.
• Peptic ulcer disease: promotes ulcer healing and prevents recurrence by suppressing acid secretion that irritates the gastric mucosa.
• Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations by creating a less acidic environment for bacterial clearance.
• Erosive esophagitis: facilitates mucosal healing by reducing acid exposure and allowing tissue regeneration.

• Lansoprazole irreversibly binds to the cysteine residues of the gastric H+/K+ ATPase enzyme, commonly known as the proton pump, located on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acid secretion, leading to an increase in gastric pH. The inhibition persists until new enzyme molecules are synthesized, providing prolonged acid suppression after a single dose.

Lansoprazole is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects

• Headache: mild to moderate pain often transient.
• Diarrhea: loose stools that may resolve with continued therapy.
• Nausea: feeling of stomach upset, usually mild.
• Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing requiring immediate medical attention.
• Clostridioides difficile infection: severe diarrhea and colitis associated with altered gut flora.
• Low magnesium levels (hypomagnesemia): muscle weakness, irregular heartbeat, or seizures with prolonged use.
• Bone fracture risk: increased incidence of hip or vertebral fractures with long‑term use.

When prescribing Lansoprazole, clinicians should consider several precautionary measures to ensure safe use.

• Assess renal function: dose adjustment may be required in patients with severe renal impairment.
• Use with caution in the elderly: increased susceptibility to electrolyte disturbances and infections.
• Monitor magnesium levels: prolonged therapy can lead to hypomagnesemia, especially in patients on diuretics.
• Avoid abrupt discontinuation: sudden stop may cause rebound acid hypersecretion and symptom recurrence.
• Consider drug interactions: review concomitant medications that may affect acid suppression or drug metabolism.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lansoprazole may alter the pharmacokinetics of several co‑administered drugs, requiring attention to potential interactions.

Major Interactions (Avoid)

• Clarithromycin: increased plasma levels of clarithromycin may raise risk of cardiac toxicity.
• Ketoconazole: reduced absorption of ketoconazole due to higher gastric pH, decreasing its efficacy.
• Atazanavir: markedly decreased atazanavir exposure, compromising antiviral activity.
• HIV protease inhibitors (e.g., ritonavir): significant reduction in drug concentrations, leading to therapeutic failure.

Moderate Interactions (Monitor Closely)

• Digoxin: modest increase in digoxin levels; monitor serum concentrations.
• Methotrexate: decreased renal clearance may raise toxicity risk; adjust dose as needed.
• Warfarin: variable effect on INR; monitor coagulation parameters regularly.